吉貝爾(688566.SH):利可君片的銷售規模處於上升期,發展前景廣闊
格隆匯7月28日丨有投資者向吉貝爾(688566.SH)提問:利可君片未來增長空間主要在哪裏?
吉貝爾回覆:升白藥整體市場容量巨大,潛力巨大,市場前景廣闊,具有巨大的市場空間和潛力,利可君片作為升白化藥領域主流的產品,未來的發展前景廣闊。一方面銷售數據分析顯示,利可君片在不同地區、城市、醫院間存在發展不均衡的現象,從全國市場來看仍然存在較大的空白市場;另一方面,腫瘤領域有效運用將為利可君片提供新的增長點,2022年5月,由國內權威腫瘤疾病專家石遠凱、顧晉等編著的《臨牀路徑釋義·腫瘤疾病分冊(2022年版)》正式出版,利可君片被作為治療惡性腫瘤疾病的推薦用藥收錄在冊:研究表明,利可君片對預防及治療惡性腫瘤患者在放療、化療過程中發生的骨髓抑制現象具有顯著效果。目前,利可君片已單獨或聯合其他藥物用於臨牀上白細胞減少症的治療,具有良好的療效。
因此,利可君片的銷售規模處於上升期,發展前景廣闊,遠未達到飽和狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.